Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy

Kim, Jong Ho; Kim, Yoo Shin; Park, Kyeongsoon; Kang, Eung Shick; Lee, Seulki; Nam, Hae Yun; Kim, Kwangmeyung; Park, Jae Hyung; Yoon, Dae; Park, Rang Woon; Kim, In San; Choi, Kuiwon; Kwon, Ick Chan

doi:10.1016/j.biomaterials.2007.12.038

Cited by 207 publications

(91 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glycol chitosan nanoparticles modified by 5β-cholanic acid (HGC) and RGD (Arg-Gly-Asp) polypeptide were easily encapsulated into nanoparticles with a drug-loading amount greater than 85%. 61 RGD-HGC nanoparticles showed a one-week sustainedrelease effect. RGD-HGC displayed antiangiogenic efficacy by inhibiting human umbilical venous cord endothelial cell adhesion to a βig-h3 protein-coated surface, markedly suppressing bFGF-induced angiogenesis as well as decreasing hemoglobin content in Matrigel plugs in vivo.…”

Section: Carrier Of Protein Drugsmentioning

confidence: 93%

See 1 more Smart Citation

Recent advances of chitosan nanoparticles as drug carriers

Zeng¹

2011

IJN

244

121

View full text Add to dashboard Cite

Chitosan nanoparticles are good drug carriers because of their good biocompatibility and biodegradability, and can be readily modified. As a new drug delivery system, they have attracted increasing attention for their wide applications in, for example, loading protein drugs, gene drugs, and anticancer chemical drugs, and via various routes of administration including oral, nasal, intravenous, and ocular. This paper reviews published research on chitosan nanoparticles, including its preparation methods, characteristics, modification, in vivo metabolic processes, and applications.

show abstract

Section: Carrier Of Protein Drugsmentioning

confidence: 93%

“…Therefore, RGD-HGC nanoparticles can inhibit tumor cell growth and reduce microvessel density significantly. 61 …”

Section: Carrier Of Protein Drugsmentioning

confidence: 99%

Recent advances of chitosan nanoparticles as drug carriers

Zeng¹

2011

IJN

244

121

View full text Add to dashboard Cite

show abstract

“…Kim et al [465] encapsulated efficiently the RGD peptide that targets the integrin alfaV-beta3 which is the most important integrin during the angiogenic processes that feed the tumors, and is expressed and exposed on the surface of …”

Section: Polymeric Nanoparticles That Incorporate Macromoleculesmentioning

confidence: 99%

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Pérez-Herrero

Fernández‐Medarde

2015

European Journal of Pharmaceutics and Biopharmaceutics

1,317

718

View full text Add to dashboard Cite

Cancer is the second worldwide cause of death, exceeded only by cardiovascular diseases. It is characterized by uncontrolled cell proliferation and an absence of cell death that, except for hematological cancers, generates an abnormal cell mass or tumor. This primary tumor grows thanks to new vasculatization and, in time, adquires metastatic potential and spreads to other body sites, which causes metastasis and finally death. Cancer is caused by damage or mutations in the genetic material of the cells due to environmental or inherited factors. While surgery and radiotherapy are the primary treatment used for local and non-metastatic cancers, anti-cancer drugs (chemotherapy, hormone and biological therapies) are the choice currently used in metastasic cancers. Chemotherapy is based on the inhibition of the division of rapidly growing cells, which is a characteristic of the cancerous cells, but unfortunately, it also affects normal cells with fast proliferation rates, like the hair follicles, bone marrow and gastrointestinal tract cells, generating the characteristic side effects of chemotherapy. The indiscriminate destruction of normal cells, the toxicity of conventional chemotherapeutic Código de campo cambiado

show abstract

“…NPs used for such matters are mostly designed to be drug-compatible, biocompatible, biodegradable, and easy to process, efficient in loading and controlling drug release [125]. In addition, modern developments in polymeric nano-formulations involve a number of homo and co-polymer combinations pertaining for sustained and controlled delivery of anti-cancer agents [126][127][128][129][130][131].…”

Section: Development Efforts On Camel Products Based Anticancer Nanopmentioning

confidence: 99%

Therapeutic Applications of Camel’s Milk and Urine against Cancer: Current Development Efforts and Future Perspectives

Alebie¹,

Yohannes²,

Worku³

2017

J Cancer Sci Ther

View full text Add to dashboard Cite

Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy

Cited by 207 publications

References 32 publications

Recent advances of chitosan nanoparticles as drug carriers

Recent advances of chitosan nanoparticles as drug carriers

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Therapeutic Applications of Camel’s Milk and Urine against Cancer: Current Development Efforts and Future Perspectives

Contact Info

Product

Resources

About